TY - JOUR
T1 - Science Signaling Podcast for 15 November 2016
T2 - A new type of kinase inhibitor
AU - Eldar-Finkelman, Hagit
AU - VanHook, Annalisa M.
N1 - Publisher Copyright:
© 2016 The Authors.
PY - 2016/11/15
Y1 - 2016/11/15
N2 - This Podcast features an interview with Hagit Eldar-Finkelman, author of a Research Article that appears in the 15 November 2016 issue of Science Signaling, about a newly developed inhibitor of glycogen synthase kinase 3 (GSK-3). GSK-3 participates in several signaling networks and has been implicated in various pathologies, including neurodegenerative diseases, cognitive impairments, and cancer. Licht-Murava et al. developed L807mts, a substrate-competitive peptide inhibitor that blocks GSK-3 activity through an unusual mechanism. L807mts not only bound to the substrate recognition domain of GSK-3, it was also phosphorylated by the kinase. This phosphorylated form of L807mts remained associated with GSK-3 and inhibited GSK-3 activity. L807mts treatment reduced cellular, cognitive, and behavioral symptoms in a mouse model of Alzheimer's disease. L807mts is an advance in kinase inhibitor development because it is both highly specific and very potent.
AB - This Podcast features an interview with Hagit Eldar-Finkelman, author of a Research Article that appears in the 15 November 2016 issue of Science Signaling, about a newly developed inhibitor of glycogen synthase kinase 3 (GSK-3). GSK-3 participates in several signaling networks and has been implicated in various pathologies, including neurodegenerative diseases, cognitive impairments, and cancer. Licht-Murava et al. developed L807mts, a substrate-competitive peptide inhibitor that blocks GSK-3 activity through an unusual mechanism. L807mts not only bound to the substrate recognition domain of GSK-3, it was also phosphorylated by the kinase. This phosphorylated form of L807mts remained associated with GSK-3 and inhibited GSK-3 activity. L807mts treatment reduced cellular, cognitive, and behavioral symptoms in a mouse model of Alzheimer's disease. L807mts is an advance in kinase inhibitor development because it is both highly specific and very potent.
UR - http://www.scopus.com/inward/record.url?scp=84995745329&partnerID=8YFLogxK
U2 - 10.1126/scisignal.aal2621
DO - 10.1126/scisignal.aal2621
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84995745329
VL - 9
JO - Science Signaling
JF - Science Signaling
SN - 1945-0877
IS - 454
M1 - pc22
ER -
